Form 8-K · Current report
Incyte 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000879169
- Accession no.
- 0000879169-26-000063
Summary
Incyte reported third-quarter 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% from a year earlier, and raised its full-year 2026 total net sales guidance to $5.21–$5.30 billion. Jakafi net sales rose 4% to $827 million, while Opzelura net sales rose 36% to $255 million and Hematology and Oncology net sales rose 38% to $235 million.
Key points
- Incyte's third-quarter 2026 R&D expenses included a one-time $1.23 billion IPR&D charge related to the acquisition of Vega Therapeutics.
- Incyte raised 2026 guidance for Opzelura net sales to $1.10–$1.12 billion and Hematology and Oncology net sales to $890–$910 million.
- Incyte said a Phase 3 study of INCA033989 in CALR-mutated myelofibrosis is expected to begin by year-end 2026.
- Incyte said topline Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa are expected by year-end 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Exhibits Description 99.1 Press release issued by Incyte Corporation dated October 29, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.